Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

PTHS - Pelthos Therapeutics Inc. Последние... | Finranks

Home

PTHS

P

Pelthos Therapeutics Inc. (PTHS)

ASE – Цена в реальном времени. Валюта: USD

22.49

-0.25 (-1.10%)

При закрытии: Mar 27, 2026, 11:07 AM EDT

22.49

0.00 (0.00%)

После закрытия: Mar 27, 2026, 6:22 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an.

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.

Видео

No Data

There is no data to display

Пресс-релизы

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an.

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.